Three clinical trials are being conducted in Brazil by our research group on the use of autologous, BM-derived, hematopoietic SCT (auto-BMHSCT) for the treatment of retinitis pigmentosa (RP), dry age-related macular degeneration and ischaemic retinopathy (including diabetic retinopathy with macular ischaemia). These studies are registered with ClinicalTrials.gov, numbers NCT01068561, NCT01518127 and NCT01518842, respectively. 1 We published the results of phase I of the clinical trial using an intravitreal injection of 0.1 mL of a cell suspension containing 0.92 Â 10 4 -2.91 Â 10 4 (mean, 1.68 Â 10 4 ) BM-derived hematopoietic stem cells (CD34 þ ) for retinal dystrophy. The second phase of this study (NCT01560715) has already begun, and now we describe the case of a participant in this study who had cystoid macular oedema (CMO) associated with RP. After this, patient underwent treatment with an intraocular injection (intravitreal) of auto-BMHSCT in which the patient showed complete resolution of the oedema 7 days after injection, and this effect remained for 1 month of follow-up, which was observed through examination using optical coherence tomography ( Figure 1 ).
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The improvement of the oedema led to an improvement in visual acuity (20/50-20/32) and an improvement in macular sensitivity, as measured by the microperimetry test (Figure 2 ). This patient had macular oedema associated with RP that started 2 years ago and had already undergone treatment with systemic carbonic anhydrase inhibitors (acetazolamide) 250 mg three times daily for 3 months and dorzolamide eye drops three times daily for 1 year without any sign of improvement in macular oedema. This group of drugs is commonly used to treat macular oedema associated with RP. [4] [5] [6] Acetazolamide increases fluid transport through the retinal pigment epithelium (RPE) by active ion transport and acidification of the RPE. 7 Macular oedema owing to low-grade inflammation may respond better to this mechanism than the diffuse loss of endothelial tight junctions that occurs in diabetes. Topical carbonic anhydrase inhibitors have a lower rate of systemic side effects than acetazolamide but are less efficacious. 4 CME that is refractory to acetazolamide treatment usually leads to permanent visual acuity loss. 5, 6 Thus, the short time of response after the injection of auto-BMHSCT is strong evidence for the action of this therapy.
The pathophysiology of macular oedema associated with retinitis is still controversial, but it may possibly be due to the blood-retinal barrier breakdown. However, the mechanism by which auto-BMHSCT led to improvement of the oedema is still subject to speculation. 7 The population of adult stem cells in the BM can restore the blood ocular barrier through a paracrine effect or interfere with the osmotic gradient, favouring the absorption of the oedema fluid. 8, 9 The results of this phase 2 clinical study are still being analysed, but this special case is the first report of an immediate clinical response using intravitreal auto-BMHSCT for the treatment of retinal disease and may open new horizons in the therapeutic possibilities for macular oedema. Further analysis of this trial will investigate this finding in the long term and determine whether there are correlations between this finding and other retinal functional or morphological changes related to intravitreal auto-BMHSCT for RP.
